Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells

Oncoscience

Volumn 2, Issue 4, 2015, Pages 395-409

  Amantini, Consuelo ^a   Morelli, Maria Beatrice ^a,b   Santoni, Matteo ^c   Soriani, Alessandra ^b   Cardinali, Claudio ^a,b   Farfariello, Valerio ^b   Eleuteri, Anna Maria ^a   Bonfili, Laura ^a   Mozzicafreddo, Matteo ^a   Nabissi, Massimo ^a   Cascinu, Stefano ^b   Santoni, Giorgio ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Akt; Bladder cancer cells; Cathepsin B; Perifosine; Sorafenib; TKI

Indexed keywords

EID: 84958529285     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.147     Document Type: Article

References (60)

1. Rose A, Grandoch M, vom Dorp F, Rübben H, Rosenkranz A, Fischer JW, Weber AA. Stimulatory effects of the multikinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol. 2010; 160: 1690-1698.
2. Wilhelm SM1, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099-7109.
3. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 2009; 115: 4090-4095.
4. Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, Tannock IF, Mukherjee SD, Wang L, Blatter C, Whrigh JJ, Moore MJ. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH phase II Consortium. Invest New Drugs. 2011; 29: 1045-1049.
5. Krege S, Rexer H, Von Dorp F, de Geeter P, Klotz T, Retz M, Heidenreich A, Kuhn M, Kamradt J, Feyerabend S, Wulfing C, Zastrow S, Albers P et al. Prospective randomized double-blind multicenter phase II study compring chemotherapy with gemcitabine and cispltin plus sorafenib vs gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer-SUSE-(AUO-AB 31/05). BJU. 2013; 113: 429-436.
6. Bambury RM, Rosenberg JE. Advanced urothelial carcinoma:overcoming treatment resistance through novel treatment approaches. Frontiers Pharmacol. 2013; 4: 1-7.
7. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009; 15: 6008-6017.
8. Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu X. Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis. 2010; 31: 1387-1391.
9. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, Cheng AL. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011; 337: 155-161.
10. Ruan ZP, Xu R, Lv Y, Tian T, Wang WJ, Guo H, Nan KJ. PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. Oncol Res. 2012; 20: 113-121.
11. Ching CB, Hansel DE. Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab Invest. 2010; 90: 1406-1414.
12. Kompier LC, Lurkin I, van der Rhijn AaMN, dan der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. Plos ONE. 2010; 5: e13821.
13. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009; 4: 127-150.
14. Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis. 2013; 4: e485.
15. Engelman JA. Targeting PI3K signaling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9: 550-562.
16. Ross AH, Gericke A. Phosphorylation keeps PTEN phosphatase closed for business. Proc Natl Acad Sci U S A. 2009; 106: 1297-1298.
17. Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol. 2001;3:E255-263.
18. Aits S, Jäättelä M. Lysosomal cell death at a glance. J Cell Sci. 2013; 126: 1905-1912.
19. Kroemer G, Jäättelä M. Lysosomes and autophagy in cell death control. Nat Rev Cancer. 2005; 5: 886-897.
20. Kirkegaard T, Jäättelä M. Lysosomal involvement in cell death and cancer. Biochim Biophys Acta. 2009; 1793: 746-754.
21. McGrath ME. The lysosomal cysteine proteases. Annu Rev Biophys Biomol Struct. 1999; 28: 181-204.
22. Ha SD, Martins A, Khazaie K, Han J, Chan BM, Kim So. Cathepsin B is involved in the trafficking of TNFalpha-containing vesicles to the plasma membrane in macrophages. J Immunol. 2008; 181: 690-697.
23. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. The NALP3 inflammosome is involved in the innate immune response to amyloid beta. Nat Immunol. 2008; 9: 857-865.
24. Willingham SB, Bergstralh DT, O'Connor W, Morrison AC, Taxman DJ, Duncan JA, Barnoy S, Venkatesan MM, Flavell RA, Deshmukh M, Hoffman HM, Ting JP. Microbial pathogen-induced necrotic cell death mediated by the inflammosome component CIAS1/cryopyrin/NLRP3 and ASC. Cell Host Microbe. 2007; 2: 147-159.
25. Turk B, Stoka V, Rozman-Pungercar J, Cirman T, Droga-Mazovec G, Oresic K, Turk V. Apoptotic pathways: involvement of lysosomal proteases. Biol Chem. 2002; 383: 1035-1044.
26. Hsu SF, Hsu CC, Cheng BC, Lin CH. Cathepsin B is involved in the heat shock induced cardiomyocytes apoptosis as well as the anti-apoptosis effect of HSP-70. Apoptosis. 2014;19:1571-80.
27. Beckham SA, Piedrafita D, Phillips CI, Samarawickrema N, Law RH, Smooker PM, Quinsey NS, Irving JA, Greenwood D, Verhelst SH, Bogyo M, Turk B, Coetzer TH et al. A major cathepsin B protease from the liver fluke Fasciola hepatica has atypical active site features and a potential role in the digestive tract of newly excysted juvenile parasites. Int J Biochem Cell Biol. 2009; 41: 1601-1612.
28. Santoni M, Amantini C, Morelli MB, Liberati S, Farfariello V, Nabissi M, Bonfili L, Eleuteri AM, Mozzicafreddo M, Burattini L, Berardi R, Cascinu S, Santoni G. Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer. 2013; 109: 1040-1050.
29. Sandes E, Lodillinsky C, Cwirenbaum R, Argüelles C, Casabé A, Eiján AM. Cathepsin B is involved in the apoptosis intrinsic pathway induced by Bacillus Calmette-Guérin in transitional cancer cell lines. Int J Mol Med. 2007; 20: 823-828.
30. Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, Schroeder A, Jensen M, Jove R. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells via dephosphorylation of STAT3. Mol Cancer Ther. 2010; 9: 953-962.
31. Chen KF, Tai WT, Hsu CY, Huang JW, Liu CY, Chen PJ, Kim I, Shiau CW. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. Eur J Med Chem. 2012; 55: 220-227.
32. Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013; 15: R63.
33. Huck O, Elkaim R, Davideau JL, Tenenbaum H. Porphyromonas gingivalis and its lipopolysaccharide differentially regulate the expression of cathepsin B in endothelial cells. Mol Oral Microbiol. 2012; 27: 137-148.
34. Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Leukemia. 2013; 27: 1677-1687.
35. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, Gores GJ. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest. 2000; 106: 1127-1137.
36. Brunk UT, Neuzil J, Eaton JW. Lysosomal involvement in apoptosis. Redox Rep. 2001; 6: 91-97.
37. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, Metivier D, Ojcius DM, Jaattela M, Kroemer G. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med. 2003; 197: 1323-1334.
38. Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, Salvesen GS, Stoka V, Turk V, Turk B. Cysteine cathepsins trigger cspase-dependent cell death through cleavage of Bid and antiapoptotic Bcl-2 homologues. J Biol Chem. 2008; 283: 19140-19150.
39. Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC, Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci U S A. 2005; 102: 192-197.
40. Green DR, Kroemer G. Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest. 2005; 115: 2610-2617.
41. Barbosa CM, Oliveira CR, Nascimento FD, Smith MC, Fausto DM, Soufen MA, Sena E, Araújo RC, Tersariol IL, Bincoletto C, Caires AC. Biphosphinic palladacycle complex mediates lysosomal-membrane permeabilization and cell death in K562 leukaemia cells. Eur J Pharmacol. 2006; 542: 37-47.
42. Turk B, Stoka V. Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett. 2007; 581: 2761-2767.
43. Ollinger K, Brunk UT. Cellular injury induced by oxidative stress is mediated through lysosomal damage. Free Radic Biol Med. 1995; 19: 565-574.
44. Antunes F, Cadenas E, Brunk UT. Apoptosis induced by exposure to a low steady-state concentration of H2O2 is a consequence of lysosomal rupture. Biochem J. 2001; 356: 549-555.
45. Stoka V, Turk B, Schendel SL,Kim T-H, Cirman T, Snipas S-J, Ellerby LS, Bredesen D, Freeze H, Abrahamanson M, Bromme D, Krajewski S, Reed JC, Yin X-M, Turk V, Salvesen GS. Lysosomal protease pathways to apoptosis cleavage of Bid, not procaspases is the most likely route. J Biol Chem. 2001; 276: 3149-3157.
46. Rafiq K, Kolpakov MA, Abdelfettah M, Streblow DN, Hassid A, Dell'Italia LJ, Sabri A. Role of protein-tyrosine phosphatase SHP2 in focal adhesion kinase down-regulation during neutrophil cathepsin G-induced cardiomyocytes anoikis. J Biol Chem. 2006; 281: 19781-19792.
47. Honma Y, Shimizu S, Takehara T, Harada M. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases. J Gastroenterol. 2014; 49: 517-526.
48. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007; 282: 29230-29240.
49. Wei Y, Ma Y, Zhao Q, Ren Z, Li Y, Hou T, Peng H. New use for an old drug: inhibiting ABCG2 with sorafenib. Mol Cancer Ther. 2012; 11: 1693-1702.
50. Dasmamapatra GP, Didolkar P, Alley M, Ghosh S, Sausville EA, Roky KK. In vitro combinatiom therapy with perifosine and UCN-9 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res. 2004; 10: 5242-5252.
51. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richarson PG, Anderson KC. Perifosine, an oral bioactive novel alkhylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006; 107: 4053-4062.
52. Fei HL, Chen G, Wang JM, Wang FZ. Perifosine induced cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. Cytotechnology. 2010; 62: 448-460.
53. Srivastava N, Cho DC. Perifosine in renal cell carcinoma. Expert Opin Investig Drugs. 2013; 22: 285-291.
54. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther. 2003; 2: 1093-1104.
55. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58: 621-681.
56. Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, Schroeder A, Jensen M, Jove R. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther. 2010; 9: 953-962.
57. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010; 31: 455-461.
58. Turk D, Podobnik M, Popovic T, Katunuma N, Bode W, Huber R, Turk V. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors. Biochemistry. 1995; 34: 4791-4797.
59. Mozzicafreddo M, Cuccioloni M, Cecarini V, Eleuteri AM, Angeletti M. Homology modeling and docking analysis of the interaction between polyphenols and mammalian 20S proteasomes. J Chem Inf Model, 2009; 49: 401-409.
60. Tchoupe JR, Moreau T, Gauthier F, Bieth JG. Photometric or fluorometric assay of cathepsin B, L and U and papain using substrates with an aminotrifluoromethylcoumarin leaving group. Biochim Biophys Acta. 1991; 1076: 149-151.